Odyssey Therapeutics

This is an exciting milestone for Odyssey, made possible by the dedication of our team, the support of our board of directors, partners and investors and the participation of patients on our clinical trials. We’re grateful to everyone who helped us get here and remain focused on advancing therapies to transform the standard of care for patients with autoimmune and inflammatory diseases.

Thank you Nasdaq for the warm welcome. This is an important milestone for Odyssey, made possible by the dedication of our team and the support of our board of directors, partners and investors. Most importantly, we’re grateful to the patients who participate in our clinical trials and inspire our work every day.

We’re pleased to welcome H. Martin Seidel, Ph.D., CEO of IFM Therapeutics, to Odyssey’s Scientific Advisory Board. Martin is a seasoned drug discovery leader who has previously worked with members of our scientific leadership team, and we look forward to his perspective as we continue advancing programs designed to precisely target disease pathology in autoimmune and inflammatory disease. https://lnkd.in/gAsCRR3W

We’re excited to welcome Jolie Siegel to Odyssey Therapeutics as our Executive Vice President and General Counsel. A seasoned life sciences legal executive, Jolie will partner with our leadership and Board to guide legal, compliance, governance, and risk management while supporting Odyssey’s ongoing strategic initiatives. Her experience supporting biotechnology companies through growth and transactions positions her to help strengthen Odyssey’s foundation as we advance our immunology programs. Learn more: https://lnkd.in/gg46dSvw

Today, we welcome Dennis Dean, Ph.D., as EVP and Head of Non-Clinical Development. With more than 25 years of experience spanning biotechnology and large pharmaceutical companies, Dr. Dean will oversee all preclinical research and development activities supporting the advancement of Odyssey’s drug candidates. He will ensure our non-clinical programs are scientifically rigorous, regulatory compliant, and strategically aligned with the company’s advancing portfolio. Learn more: https://lnkd.in/gbPXFaJ4

We are excited to welcome Nia Tatsis, PhD, to our Board of Directors!       With decades of senior-level leadership experience in global biopharmaceutical companies – including her current role serving as EVP and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals – Dr. Tatsis brings a wealth of knowledge that will be invaluable as we work to deliver transformative medicines to patients in need.      Learn more: https://lnkd.in/gckgAtxW

Today, we announce the closing of a $213M Series D financing round. Thank you to our existing and new investors for supporting the advancement of our portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. Learn more: https://lnkd.in/g7tdvFvg